title: Statins use and risk of cataracts: firm conclusions are still far off.
authors.affiliation: Division of Pharmacoepidemiology and Pharmacovigilance, Spanish Medicines and Healthcare Products Agency (AEMPS), Madrid, Spain dmacias.sg@gmail.com.
authors.forename: Diego Macías
authors.initials: DM
authors.lastname: Saint-Gerons
authors.affiliation: Division of Pharmacoepidemiology and Pharmacovigilance, Spanish Medicines and Healthcare Products Agency (AEMPS), Madrid, Spain.
authors.forename: César de la Fuente
authors.initials: Cde L
authors.lastname: Honrubia
authors.affiliation: Division of Pharmacoepidemiology and Pharmacovigilance, Spanish Medicines and Healthcare Products Agency (AEMPS), Madrid, Spain.
authors.forename: Dolores
authors.initials: D
authors.lastname: Montero
authors.affiliation: Division of Pharmacoepidemiology and Pharmacovigilance, Spanish Medicines and Healthcare Products Agency (AEMPS), Madrid, Spain.
authors.forename: Diana
authors.initials: D
authors.lastname: González-Bermejo
authors.affiliation: Department of Pharmacology, School of Medicine, University Complutense of Madrid, Madrid, Spain.
authors.forename: Fernando
authors.initials: F
authors.lastname: de Andrés-Trelles
authors.affiliation: Division of Pharmacoepidemiology and Pharmacovigilance, Spanish Medicines and Healthcare Products Agency (AEMPS), Madrid, Spain.
authors.forename: Ferrán
authors.initials: F
authors.lastname: Catalá-López
mesh_terms: D000818:Animals; D002386:Cataract / Q000175:diagnosis* / Q000517:prevention & control*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors